Cite
MLA Citation
Willem Hettema et al.. “A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects.” Expert opinion on investigational drugs, vol. 26, 2017, pp. 889–896. http://access.bl.uk/ark:/81055/vdc_100047976723.0x000047